Literature DB >> 15479438

Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein.

Mangala Rao1, Gary R Matyas, Thomas C Vancott, Deborah L Birx, Carl R Alving.   

Abstract

In the present study we investigated the immunomodulatory effects of two adjuvants, liposomal lipid A [L(LA)] and CpG-containing oligodeoxynucleotides (CpG ODN), to the HIV-1 ogp140 envelope protein. Administration of each of these adjuvants separately with unencapsulated ogp140 resulted in low antibody titres. Encapsulation of ogp140 in liposomes containing lipid A resulted in a sixfold increase in anti-ogp140 antibodies. The antibody titres were further enhanced threefold by the addition of CpG ODN. Priming and boosting BALB/c mice with unencapsulated ogp140 with L(LA) or encapsulation in liposomes containing lipid A induced a mixed Th1/Th2 type of immune response. In contrast, immunization with L(ogp140 + LA) plus CpG ODN switched the immune response to a Th-1 response with elevated anti-ogp140 IgG2a antibodies and IFN-gamma levels. Both adjuvants induced excellent ogp140-specific proliferative and CTL responses. Therefore, for the induction of high titre antibodies, but not for cellular responses, the antigen and lipid A have to be present in the same liposomes. These results can have significant implications in directing the Th1 or Th2 differentiation of antigen-specific immune responses in the context of vaccine development. Copyright 2004 Australasian Society for Immunology Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479438     DOI: 10.1111/j.0818-9641.2004.01283.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  7 in total

Review 1.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

2.  Highly effective generic adjuvant systems for orphan or poverty-related vaccines.

Authors:  Mangala Rao; Kristina K Peachman; Qin Li; Gary R Matyas; Sathish B Shivachandra; Richard Borschel; Venee I Morthole; Carmen Fernandez-Prada; Carl R Alving; Venigalla B Rao
Journal:  Vaccine       Date:  2010-11-27       Impact factor: 3.641

3.  Assembly of human immunodeficiency virus (HIV) antigens on bacteriophage T4: a novel in vitro approach to construct multicomponent HIV vaccines.

Authors:  Taheri Sathaliyawala; Mangala Rao; Danielle M Maclean; Deborah L Birx; Carl R Alving; Venigalla B Rao
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Gag p24 alters the composition of immunoproteasomes and affects antigen presentation.

Authors:  Nicholas J Steers; Kristina K Peachman; Sasha R McClain; Carl R Alving; Mangala Rao
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

5.  A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.

Authors:  Aneesh Vijayan; Juan García-Arriaza; Suresh C Raman; José Javier Conesa; Francisco Javier Chichón; César Santiago; Carlos Óscar S Sorzano; José L Carrascosa; Mariano Esteban
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

Review 6.  Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines.

Authors:  Luis O De Serrano; David J Burkhart
Journal:  J Nanobiotechnology       Date:  2017-11-17       Impact factor: 10.435

7.  Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine.

Authors:  Alexander N Zakhartchouk; Chetna Sharon; Malathy Satkunarajah; Thierry Auperin; Sathiyanarayanan Viswanathan; George Mutwiri; Martin Petric; Raymond H See; Robert C Brunham; B Brett Finlay; Cheryl Cameron; David J Kelvin; Alan Cochrane; James M Rini; Lorne A Babiuk
Journal:  Vaccine       Date:  2006-08-02       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.